


Pediatric COVID-19 Vaccine Dosing Quick Reference Guide









12 years and older




 $[\]textbf{a. For children who turn 4} to 5 years during their vaccine series, follow dosing recommendations based on age at the \underline{start} of the vaccine series.$


Pediatric COVID-19 Vaccine Dosing Quick Reference Guide


American Academy of Pediatrics DEDICATED TO THE HEALTH OF ALL CHILDRENS



For Individuals who are Moderately to Severely Immunocompromised







- a. For children who turn 4 to 5 years during their vaccine series, follow dosing recommendations based on age at the start of the vaccine series.
- b. For children who turn 11 to 12 years during their vaccine series, follow dosing recommendations based on age at the time of vaccination.
- c. Children who are moderately to severely immunocompromised have the option to receive one additional homologous dose of updated mRNA vaccine at least 8 weeks after the last recommended dose. Further additional homologous doses may be administered at ≥8 week intervals, informed by clinical judgment of the health care provider and personal preference and circumstances.

d. Individuals who are moderately to severely immunocompromised have the option to receive one additional dose of updated mRNA vaccine at least 8 weeks following the last recommended dose. Further additional doses may be administered at ≥8 week intervals, informed by clinical judgement of the healthcare provider and personal preference and circumstances.


Pediatric COVID-19 Vaccine Dosing Quick Reference Guide


Novavax COVID-19 Vaccine




DEDICATED TO THE HEALTH OF ALL CHILDREN®









e. In limited situations where mRNA vaccine is contraindicated, unavailable, or declined and a booster dose has not been previously administered.

f. Individuals who are moderately to severely immunocompromised have the option to receive one additional dose of updated mRNA vaccine at least 8 weeks following the last recommended dose. Further additional doses may be administered at ≥8 week intervals, informed by clinical judgement of the healthcare provider and personal preference and circumstances.